Skip to main content
. 2016 Jun 9;115(1):59–65. doi: 10.1038/bjc.2016.175

Figure 2.

Figure 2

The results of the ctDNA detection.(A) Frequency of KRAS mutations in all primary tumour specimens and plasma samples. (B) Scattergram of ctDNA concentrations in all patients subdivided according to the Union for International Cancer Control (UICC) classification.